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The physiology of SPC flow involves both beneficial and deleterious effects. 1, 2 SPCs can augment blood flow to hypoperfused lung segments, improve gas exchange, and potentially inhibit the development of pulmonary arteriovenous malformations in patients in whom hepatic venous flow does not reach the pulmonary circulation. In contrast, like other shunts, SPC flow is inherently inefficient because relatively highly oxygenated blood returns to the pulmonary circulation and potentially competes with the more efficient antegrade flow to the lungs through the native pulmonary arteries. Consequently, SPC flow results in volume load on the FSV, which can lead to ventricular dilatation and dysfunction, atrioventricular valve regurgitation, and heart failure symptoms. Other deleterious effects of excessive SPCs include flow energy loss, 7 exuberant blood flow returning through the pulmonary veins to the surgical field during cardiopulmonary bypass, respiratory distress, pulmonary hypertension, and hemoptysis. 8 In patients with FSV, the hemodynamic burden from SPCs has been the topic of particular concern because the FSV is thought to be vulnerable to ventricular dysfunction and elevated pulmonary vascular resistance can lead to complications such as low cardiac output, central venous hypertension, pleural effusions, ascites, and protein-losing enteropathy.
The optimal management strategy of SPCs in patients with FSV continues to be the subject of debate. On 1 end of the spectrum are those who occlude SPCs only in highly selected circumstances, usually when large collaterals with exuberant flow are considered the cause of clinical compromise. 4 Advocates of this selective approach cite absence of evidence that routine occlusion of smaller SPCs results in improved clinical outcomes such as shorter duration of postoperative pericardial and pleural effusions, shorter hospital stay, lower incidence of ventricular dysfunction, or lower mortality. On the other end of the spectrum are those who routinely target most SPCs. 2, 5, 9 The rationale cited by those who favor this strategy is based on the potential for unfavorable hemodynamics due to excessive SPC flow, which may adversely affect early and late clinical outcomes. This disparate practice was recently documented by Banka et al, 10 who found that the incidence of SPC coil occlusion among the 7 centers that participated in the Pediatric Heart Network Fontan CrossSectional study varied from 0% to 30%. Adding to the controversy on the use of routine coil occlusion of SPCs, multivariable analysis in their nonrandomized cohort found no significant differences in hospital length of stay, postoperative complications, or patient outcomes at cross-sectional evaluation 8.6Ϯ3.4 years after Fontan between those who received coil occlusion and those who did not.
Until recently, the debate regarding the clinical impact of SPC flow and the efficacy of transcatheter occlusion strategies has been marred by lack of a reliable in vivo method to measure the amount of blood flow carried by these collaterals. In the absence of an optimal quantitative, noninvasive technique to measure SPC flow, investigators were unable to reliably determine the hemodynamic burden caused by these collaterals and to objectively evaluate the efficacy of coil occlusion during cardiac catheterization. [1] [2] [3] 11 The recent development of a cardiac MR technique to measure SPC flow noninvasively has overcome the drawbacks of previous methods to quantify collateral flow in patients with FSV. 12 First described in a case report by Grosse-Wartmann et al in 2007, 13 this method was subsequently refined and systematically evaluated in small cohorts by the same group and by Whitehead et al. 14, 15 Using phase contrast cine cardiac MR flow measurements in the aorta, superior and inferior venae cavae, branch pulmonary arteries, and pulmonary veins, SPC flow can be calculated in 2 different ways: (1) SPC flowϭsum of pulmonary vein flowϪsum of branch pulmonary artery flow; and (2) SPC flowϭascending aorta flowϪsum of caval flow (Figure) . The results of both methods are then compared with each other for consistency as a measure of internal control. In addition to total SPC flow, this technique also provides information on the amount of collateral flow in each lung.
In this issue of Circulation: Cardiovascular Imaging, Glatz et al 16 report that higher SPC flow measured by cardiac MR in 44 patients before Fontan surgery was associated with longer postoperative duration of chest tube drainage and longer hospital length of stay after adjusting for presence of baffle fenestration and Fontan type. Keeping in mind the small sample size and the selective cohort (only 44 of 162 contemporaneous Fontan patients underwent SPC flow quantification by cardiac MR), the investigators found that higher SPC flow was a risk factor for chest tube duration Ն10 days either when expressed in absolute terms (OR, 22.4; 95% CI, 2.2-239 for an increase of 1 L/min/m 2 ) or when expressed as percentage of aortic flow (OR, 1.24; 95% CI, 1.06 -1.4 for an increase of 1%) or pulmonary venous flow (OR, 1.18; 95% CI, 1.05-1.34 for an increase of 1%). The data regarding length of hospital stay is mixed in that SPC flow was associated with postoperative hospitalization of Ն7 days but not of Ն14 days. Furthermore, there was a weak linear correlation between duration of hospitalization and SPC flow expressed as percentage of aortic flow (Spearman rank correlation coefficientϭ0.31, Pϭ0.04) and pulmonary venous flow (Spearman rank correlation coefficientϭ0.29, Pϭ0.05) but not with absolute SPC flow. Taken together, this study suggests an association between SPC flow measured by cardiac MR and early post-Fontan surgery complications and resource use. It is important, however, to recognize that the retrospective study design does not allow the establishment of a cause-and-effect relationship between SPC flow and outcomes, and additional unmeasured confounders may have influenced the results.
The study of Glatz et al as well as those of other investigators 14, 15, 17 highlight both challenges and opportunities presented by the development and initial clinical application of the newly developed cardiac MR method to measure SPC flow. Although flow measurement by phase velocity cine MRI is an established technique that has been validated extensively in vitro and in vivo, 18, 19 several challenges in the application of this technique to SPC flow quantification in patients with FSV are worth noting. In the absence of an in vivo reference standard for flow measurements, it is difficult to confirm the accuracy of SPC flow measurements in patients with FSV. On the other hand, the cardiac MR approach allows for internal assessment of consistency by comparing 2 distinct sets of flow measurements as well as comparison between ventricular stroke volumes measured by cine MR and aortic stroke volume measured by the phase contrast technique. Another challenge is the reproducibility of the flow measurements in patients with FSV. The interobserver reproducibility reported by Glatz et al (intraclass correlation coefficientϭ0.8) and by Grosse-Wartmann et al (intraclass correlation coefficientϭ0.73) is modest, likely due to compounding measurement variations from multiple samples included in the calculation of SPC flow. In addition, flow measurement in the inferior vena cava can be challenging due to the short distance between the entrances of the hepatic veins and the atrial floor as well as the swirling, inhomogeneous low-velocity flow profile. Another unresolved question is whether flow measurement in the descending aorta just below the diaphragm can reliably substitute for flow measurement in the inferior vena cava. An advantage of substituting descending aorta flow for inferior vena cava flow is the more organized flow profile, which potentially results in a more accurate measurement. The pitfall of this approach is that SPCs originating below the diaphragm and decompressing veins in pre-Fontan patients are excluded from the calculation, thus underestimating SPC flow. Finally, from a logistic standpoint, the acquisition time of 8 to 9 cine phase contrast MRI sequences (Figure) usually exceeds 20 minutes, depending on heart rate and imaging parameters that determine spatial and temporal resolutions. The clinical use and accuracy of faster acquisition strategies, including breathhold and real-time techniques, 20 are yet to be tested in this patient group.
The study of Glatz et al also highlights new opportunities to gain insights into the clinical consequences of SPC flow in patients with FSV and the efficacy of transcatheter therapy. Given that the available literature indicates that equipoise exists with regard to highly selective versus routine ap- proaches to catheter-based occlusion of SPCs in patients with FSV, the time is now ripe for a prospective randomized clinical trial to determine which approach provides superior early and midterm clinical benefits. The newly developed cardiac MR technique for SPC flow measurement can be instrumental for patient selection and baseline characterization as well as for assessment of treatment efficacy. In parallel to this effort, a prospective observational multicenter cohort using standardized data collection can inform us about the natural history of SPCs in patients with FSV and how this cardiac MR technique can be used for risk stratification. Studies with this quantitative tool, if properly validated and applied, will provide better data to standardize practice and improve outcomes for patients with complex congenital heart disease.
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